PRITHVIRAJ BOSE to Drug Resistance, Neoplasm
This is a "connection" page, showing publications PRITHVIRAJ BOSE has written about Drug Resistance, Neoplasm.
Connection Strength
0.380
-
Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017 09; 58(9):1-17.
Score: 0.220
-
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 09; 18(9):569-575.e1.
Score: 0.060
-
Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 03; 18(3):17.
Score: 0.055
-
Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.
Score: 0.017
-
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.
Score: 0.016
-
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma. 2016; 57(3):635-43.
Score: 0.013